돌연변이 p53 단백질의 Silencing에 의한 사람유방암세포의 in vivo 항종양 효과

• Published in: KSBB Journal Vol. 31; no. 1; pp. 52 - 57
• Main Authors: 박원익(Won Ick Park), 박세라(Se-Ra Park), 박현주(Hyun-Joo Park), 배윤희(Yun-Hee Bae), 유현수(Hyun Su Ryu), 장혜옥(Hye-Ock Jang), 배문경(Moon-Kyoung Bae), 배수경(Soo-Kyung Bae)
• Format: Journal Article
• Language: Korean
• Published: 한국생물공학회 01.03.2016
• Subjects: 생물공학; Breast cancer; Xenograft tumor model; Mutant p53; Apoptosis
• ISSN: 1225-7117; 2288-8268
• DOI: 10.7841/ksbbj.2016.31.1.52

Mutant p53 (R280K) is highly expressed in MDAMB- 231 triple-negative human breast cancer cells. Currently, we reported the role of mutant p53-R280K in mediating the survival of MDA-MB-231 cells in vitro. The present study was undertaken to determine whether mutant p53-R280K affects breast cancer cell growth in vivo. To this end, we used small interfering RNA to knockdown the level of mutant p53- R280K in MDA-MB-231 cells. Silencing of mutant p53- R280K in MDA-MB-231 cells causes substantial tumor regression of established xenografts in vivo. In xenograft model for breast cancer, silencing of mutant p53-R280K in MDAMB- 231 cells significantly inhibited the tumor growth. Moreover, TUNEL assay showed more occurrence of apoptotic cells in mutant p53-R280K silenced tumors compared to control. Our data indicate that mutant p53-R280K has an important role in mediating tumor growth of MDA-MB-231 cells in vivo. Taken together, this study suggests that endogenous mutant p53-R280K could be used as a therapeutic target for breast cancer cells harboring this TP53 missense mutation. KCI Citation Count: 0